Dipal Doshi, President and CEO at Entrada Therapeutics, Inc. (TRDA), sold 2,000 shares at $12.00 ($25K) on 2022-08-31, disclosed to the SEC on 2022-08-31.
Scheduled sale ($25k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.56 | 1,109 | $14K | 54.8% |
| 2 | $13.51 | 505 | $7K | 26.8% |
| 3 | $14.00 | 25 | $350 | 1.4% |
| 4 | $12.00 | 190 | $2K | 9.0% |
| 5 | $12.00 | 171 | $2K | 8.1% |
| Total | $12.72 avg | 2,000 |
| $25K |
| 100% |
| Filing → |
| TRDA | SELL | 2024-05-20 | $45K | — | Filing → |
| TRDA | SELL | 2024-02-20 | $15K | — | Filing → |
| TRDA | SELL | 2024-01-18 | $16K | — | Filing → |